Business / Finance

RSS

INTEGRA Biosciences acquires Miroculus to accelerate genomics

INTEGRA Biosciences is delighted to announce that it has acquired Miroculus, a biotechnology specialist focused on developing hands-off automation solutions for next generation sequencing (NGS) protocols.

From INTEGRA Biosciences 20 Mar 2023

PerkinElmer completes divestiture of its applied, food and enterprise services businesses

...

From PerkinElmer 14 Mar 2023

Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment

Investors include Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, and Angel investors, with support from KPMG Acceleris.

From Five Alarm Bio 28 Feb 2023

Tecan collaborates with Singular Genomics to take automated NGS library preparation into the future

Tecan has partnered with Singular Genomics to use the turnkey MagicPrep™ NGS system* to create sequencing-ready libraries for the G4™ Sequencing Platform.

From Tecan 13 Feb 2023

Valent BioSciences announces the acquisition of FBSciences

Valent BioSciences LLC, a global leader in the discovery, development, and commercialization of highly effective, low-risk, environmentally compatible technologies and products for agriculture, public health, and forest health, announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions.

From Valent Biosciences 13 Feb 2023

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Cerba Research announced today a Memorandum of Understanding with Teddy Clinical Research Laboratory (Wuxi, China), a preeminent central lab provider covering mainland China, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture.

From Cerba Research 3 Feb 2023

Xylem To Acquire Evoqua in $7.5 Billion All-Stock Transaction

Xylem Inc. (NYSE: XYL), a leading global water technology company (“Xylem”), and Evoqua (NYSE: AQUA), a leader in mission-critical water treatment solutions and services, today announced they have entered into a definitive agreement under which Xylem will acquire Evoqua in an all-stock transaction that reflects an implied enterprise value of approximately $7.5 billion.

From Xylem Analytics 25 Jan 2023

TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies

New company created to enable commercial manufacture of new cell and gene therapies.

From TTP plc 17 Jan 2023

Optibrium appoints Steve Yemm as Chief Commercial Officer

New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team.

From Optibrium Ltd. 17 Jan 2023

The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

Expansion of five-year collaboration broadens established Organ-on-a-chip research demonstrating advanced performance of the PhysioMimix MPS.

From CN Bio Innovations Limited 17 Jan 2023

Sartorius BIA Separations and Exopharm Sign Joint Research Agreement to Develop Integrated Technology

Sartorius BIA Separations (BIA), a leading bio-chromatography company, now part of the international life science group Sartorius, and Exopharm Ltd. (ASX:EX1), a company at the forefront of transformative medicines using exosomes, or extracellular vesicles (EVs), today announced they had entered into a formal collaboration.

23 Nov 2022

The Native Antigen Company Strengthens Senior Team to Support Growing Product Portfolio

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced two key appointments to its management team.

From The Native Antigen Company 23 Nov 2022

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.

From FUJIFILM Corporation 22 Nov 2022

Andor Launches New ZL41 Cell and Sona sCMOS Cameras

Andor Technology, an Oxford Instruments company and a world leader in scientific imaging solutions, has today announced the launch of two new scientific CMOS cameras, specifically designed for life science researchers.

From Andor Technology Ltd. 7 Nov 2022

Sphere Fluidics opens new laboratory facilities at Granta Park in Cambridgeshire, UK

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth.

From Sphere Fluidics Limited 25 Oct 2022

Porous PTFE components for demanding applications

Specialists in innovative porous plastics technologies – Porvair Sciences has introduced a new range of Vyon® PTFE porous plastic materials for applications where temperature or chemical resistance is important.

From Porvair Sciences Limited 19 Oct 2022

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse

Actylis Integrates Aceto and its 10 Acquired Specialists with Broad Expertise in GMP and Non-GMP Raw Material Manufacturing and Sourcing into a Singular Global Brand

From Actylis 28 Sep 2022

H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support

Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research

From H.E.L Group 6 Sep 2022

Healthcare super fund HESTA directly invests in Inventia Life Science

Inventia Life Science has today announced that HESTA have invested AU$4.4 million in Inventia Life Science.

From Inventia Life Science 16 Aug 2022

Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market

Company aims to democratise access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform